Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology

Chemical Research in Toxicology

Volumn 19, Issue 7, 2006, Pages 889-893

  Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PROTEIN;

DRUG ACTIVATION; DRUG DESIGN; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG RESEARCH; REVIEW; TOXICITY TESTING; XENOBIOTIC METABOLISM;

BIOTRANSFORMATION; DRUG DESIGN; METABOLIC DETOXICATION, DRUG; SIGNAL TRANSDUCTION; TOXICOLOGY;

EID: 33746255370     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx060062o     Document Type: Review

References (30)

1. Schmid, E. F., and Smith, D. A. (2005) Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today 10, 1031-1039.
2. MacCoss, M., and Baillie, T. A. (2004) Organic chemistry in drug discovery. Science 303, 1810-1813.
3. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-716.
4. Olsen, H., Betton, G., Robinson, D., Thomas, K., Munro, A., Kolaja, G., Lilly. P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and animals. Regul. Toxicol. Pharmacol. 32, 56-67.
5. U.S. Department of Health and Human Services, Food and Drug Administration (2004) Challenges and opportunity on the critical path to new medical products, http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html.
6. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein covalent adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
7. Kalgutkar, A. S., and Soglia, J. R. (2005) Minimising the potential for metabolic activation in drug discovery. Exp. Opin. Drug Metab. Toxicol. 1, 91-142.
8. Yin, W., Mitra, K., Stearns, R. A., Baillie, T. A., and Kumar, S. (2004) Conversion of the 2,2,6,6-tetramethylpiperidine moiety to a 2,2- dimethylpyrrolidine by cytochrome P450: Evidence for a mechanism involving nitroxide radicals and heme iron. Biochemistry 43, 5455-5466.
9. Doss, G. A., Miller, R. R., Zhang, Z., Teferra, Y., Nargund, R. P., Palucki, B., Park, M. K., Tang, Y. S., Evans, D. C., Baillie, T. A., and Stearns, R. A. (2005) Metabolic activation of a 1,3-disubstituted piperazine derivative: Evidence for a novel ring contraction to an imidazoline. Chem. Res. Toxicol. 18, 271-276.
10. Singh, R., Silva-Elipe, M. V., Pearson, P. G., Arison, B. H., Wong, B. K., White, R., Yu, X., Burgey, C. S., Lin, J. H., and Baillie, T. A. (2003) Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement and covalent binding to proteins. Chem. Res. Toxicol. 16, 198-207.
11. Reddy, V. B. G., Karanam, B. V., Gruber, W. L., Wallace, M. A., Vincent, S. H., Franklin, R. B., and Baillie, T. A. (2005) Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. Chem. Res. Toxicol. 18, 880-888.
12. 1 receptor antagonists: Irreversible binding to liver microsomal proteins and formation of glutathione conjugates. Chem. Res. Toxicol. 18, 934-945.
13. Zhang, Z., Chen, Q., Li, Y., Doss, G. A., Dean, B. J., Ngui, J. S., Silva-Elipe, M., Kim, S., Wu, J. Y., DiNinno, F., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2005) In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: Formation of reactive iminium and quinine type metabolites. Chem. Res. Toxicol. 18, 675-685.
14. Tirmenstein, M. A., and Nelson, S. D. (1989) Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxy-acetanilide, in mouse liver. J. Biol. Chem. 264, 9814-9819.
15. Axworthy, D. B., Hoffmann, K.-J., Streeter, A. J., Calleman, C. J., Pascoe, G. A., and Baillie, T. A. (1988) Covalent binding of acetaminophen to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of the arylating metabolites. Chem.-Biol. Interact. 68, 99-116.
16. Dahlin, D. C., Miwa, G. T., Lu, A. Y. H., and Nelson, S. D. (1984) N-Acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. U.S.A. 81, 1327-1331.
17. Chen, W., Shockor, J. P., Tonge, R., Hunter, A., Gartner, C., and Nelson, S. D. (1999) Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38, 8159-8166.
18. Baillie, T. A., and Slatter, J. G. (1991) Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo. Acc. Chem. Res. 24, 264-270.
19. Hoffmann, K.-J., Streeter, A. J., Axworthy, D. B., and Baillie, T. A. (1985) Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins. Mol. Pharmacol. 27, 566-573.
20. Streeter, A. J., Bjorge, S. M., Axworthy, D. B., Nelson, S. D., and Baillie, T. A. (1984) The microsomal metabolism and site of covalent binding to protein of 3′-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. Drug Metab. Dispos. 12, 565-576.
21. Dennehy, M. K., Richards, K. A. M., Wernke, G. R., Shyr, G. R., and Liebler, D. C. (2006) Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem. Res. Toxicol. 19, 20-29.
22. Liebler, D. C., and Guengerich, F. P. (2005) Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discovery 4, 410-420.
23. Uetrecht, J. P. (1999) New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12, 387-395.
24. Shenton, J. M., Chen, J., and Uetrecht, J. P. (2004) Animal models of idiosyncratic drug reactions. Chem.-Biol. Interact. 150, 53-70.
25. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202.
26. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361.
27. Zhou, S., Chan, E., Duan, W., Huang, M., and Chen, Y.-Z. (2005) Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 1, 41-213.
28. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discovery 4, 489-499.
29. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., and Brodie, B. B. (1973) Acetaminophen-induced hepatic necrosis. 1. The role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185-194.
30. Liebler, D. C. (2006) The poisons within. Application of toxicology mechanisms to fundamental disease processes. Chem. Res. Toxicol. 19, 610-613.